Black Diamond Therapeutics, Inc. financial data

Symbol
BDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, 14 Th Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Aset Therapeutics, Inc. (to 1/4/2018)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 753 % -6.49%
Debt-to-equity 35.6 % +3.64%
Return On Equity -72.9 % -5.25%
Return On Assets -53.8 % -4.29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.7M shares +41.6%
Common Stock, Shares, Outstanding 52.5M shares +43.9%
Entity Public Float 115M USD +106%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 51.8M shares +42%
Weighted Average Number of Shares Outstanding, Diluted 51.8M shares +42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 58.1M USD -5.31%
General and Administrative Expense 27M USD -1.11%
Operating Income (Loss) -85.1M USD +4.02%
Nonoperating Income (Expense) 5.35M USD +21%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -79.8M USD +7.79%
Earnings Per Share, Basic -1.66 USD/shares +30.5%
Earnings Per Share, Diluted -1.66 USD/shares +30.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.4M USD -35.1%
Assets, Current 119M USD +10%
Property, Plant and Equipment, Net 1.64M USD -29.5%
Operating Lease, Right-of-Use Asset 21.3M USD -11.8%
Other Assets, Noncurrent 0 USD -100%
Assets 143M USD +5.12%
Accounts Payable, Current 1.18M USD -61.4%
Employee-related Liabilities, Current 2.51M USD +37.5%
Accrued Liabilities, Current 15.7M USD +60%
Liabilities, Current 16.9M USD +31.2%
Operating Lease, Liability, Noncurrent 21.4M USD -13%
Liabilities 38.2M USD +2.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -95K USD +91.9%
Retained Earnings (Accumulated Deficit) -436M USD -22.4%
Stockholders' Equity Attributable to Parent 104M USD +6.23%
Liabilities and Equity 143M USD +5.12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.2M USD -5.83%
Net Cash Provided by (Used in) Financing Activities 4.13M USD +7998%
Net Cash Provided by (Used in) Investing Activities -13.7M USD -155%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 52.5M shares +43.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -30.8M USD -738%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.2M USD -34.9%
Deferred Tax Assets, Valuation Allowance 111M USD +26.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 117M USD +24%
Operating Lease, Liability 24.5M USD -10.6%
Depreciation 86K USD -29.5%
Payments to Acquire Property, Plant, and Equipment 33K USD -82.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -78.7M USD +8.41%
Lessee, Operating Lease, Liability, to be Paid 29.3M USD -12.7%
Property, Plant and Equipment, Gross 2.53M USD -20.4%
Operating Lease, Liability, Current 3.18M USD +9.49%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.6M USD +2.73%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.48M USD +2.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.78M USD -22.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.72M USD +2.72%
Deferred Tax Assets, Operating Loss Carryforwards 69.2M USD +14.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.93M USD -16.9%
Operating Lease, Payments 1.08M USD +2.76%
Additional Paid in Capital 540M USD +18.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5.93M USD -9.88%
Share-based Payment Arrangement, Expense 8.65M USD -24.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%